


Contents

Editors	xii
Contributors	xvi
Reviewers	xxii
Abbreviations	xxv
Acknowledgements	xxxiii
Preface	xxxiv



Section 1: Introduction to immunology and immunotherapy

1.1 Immune Checkpoints	3
Definition	3
Immune Synapse	4
Technical Procedures	7
Predictive and/or Prognostic Biomarkers of (Potential)	
Clinical Relevance	8
Clinical Results	10
Potential Future Developments	13
Further Reading	14
1.2 Adoptive T Cell Therapy	15
Naturally Occurring Tumour-specific T Cells	15
Genetically Modified T Cells	17
Concluding Remarks	22
Further Reading	22

1.3 Vaccines (Dendritic Cell Vaccines, Peptide Vaccines, DNA Vaccines, RNA Vaccines, Oncolytic Viruses)	23
Definition (Introduction to the Concept and Development of Cancer Vaccine Strategies)	23
Essential Processes Involved	26
Dendritic Cell Vaccines	27
Peptide Vaccines	31
DNA Vaccines	34
RNA Vaccines	35
Oncolytic Viruses	36
Predictive and/or Prognostic Biomarkers of (Potential) Clinical Relevance	37
Potential Future Developments	37
Further Reading	40
1.4 Biomarkers for Immunotherapy	43
Introduction	43
Biological Background for Biomarkers in Immunotherapy	43
Future Immuno-oncology Biomarker Strategies	53
Conclusion	53
Further Reading	54
1.5 Resistance to Immunotherapy	56
Introduction	56
Tumour-intrinsic Mechanisms of Immune Checkpoint Inhibitor Resistance	57
Tumour-extrinsic Mechanisms of Immune Checkpoint Inhibitor Resistance	63
Environmental Host Factors	64
Unmet Needs	66
Further Reading	67
 Section 2: Immunotherapies in specific disease groups – State of the art	
2.1 Melanoma	73
Overview of Immunotherapy in Melanoma	73

Immunotherapy in Metastatic/Unresectable Melanoma	74
Adjuvant Immunotherapy in Melanoma	79
Immunotherapy Versus Targeted Therapy	81
The Endless Search for a Biomarker	82
Future Perspectives	83
Further Reading	85
2.2 Merkel Cell Carcinoma	87
Overview	87
Introduction	87
Immunology of MCC	88
Immunotherapy of MCC	90
Unmet Needs and Future Directions	94
Conclusion	96
Further Reading	96
2.3 Thoracic Malignancies	
2.3.1 Non-small Cell Lung Cancer	99
Current Scope of Immunotherapy of NSCLC	99
Predictive Biomarkers of Immunotherapy Response of Clinical Relevance	100
Immunotherapy of Locally Advanced NSCLC	105
Immunotherapy of Early-stage NSCLC	105
Potential Future Developments	107
Further Reading	111
2.3.2 Small Cell Lung Cancer	112
Introduction	112
Rationale for Immunotherapy in SCLC and Predictors of Response	114
Clinical Results	115
Future Developments	118
Further Reading	123
2.3.3 Mesothelioma	125
Definition	125
Predictive and/or Prognostic Biomarkers of Clinical Relevance	125

Clinical Results	126
Potential Future Developments	129
Further Reading	131
2.3.4 Other Thoracic Malignancies: Thymic Malignancies and Others	133
Thymic Malignancies	133
Other Rare Thoracic Malignancies	138
Further Reading	140
2.4 Genitourinary Malignancies	
2.4.1 Renal Cancer	142
Introduction	142
Clinical Results	143
Potential Future Developments	148
Conclusion	151
Further Reading	152
2.4.2 Bladder Cancer	154
Introduction and Context	154
Clinical Results	156
Potential Future Developments	161
Further Reading	164
2.5 Gastrointestinal Malignancies	
2.5.1 Microsatellite Instability-high	166
Pathogenesis of Microsatellite Instability	167
Who Does This Apply To?	168
Clinical, Pathological and Genetic Criteria Involved in Detection of Mismatch Repair Deficiency	169
Historical Prognostic and Predictive Value of MSI	171
Clinical Rationale of Using MSI as a Predictive Biomarker for Programmed Cell Death Protein 1 Antibody Response	172
Clinical Implications	173
Further Reading	175

2.5.2 Gastric and Oesophageal Malignancies	178
Introduction	178
The Immune Environment in Gastro-oesophageal Cancer	178
Immune Checkpoint Blockade in Gastro-oesophageal Cancer	179
Squamous Oesophageal Cancer	187
Conclusions and Future Directions	188
Further Reading	189
2.5.3. Hepatocellular Carcinoma	191
Introduction	191
HCC Immunobiology	192
Current Landscape of Immune Checkpoint Inhibition in HCC	193
Alternative Immunotherapeutic Strategies	198
Future Directions and Issues Specific to HCC	199
Conclusions	201
Further Reading	202
2.6 Immunotherapy in Head and Neck Tumours (HPV+ and HPV-)	203
Immunotherapy in Head and Neck Cancer – the Rationale	203
Immunotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma	205
Immunotherapy in Recurrent/Metastatic Head and Neck Cancer – Evidence and Future Directions	208
Immuno-oncology in Head and Neck Cancer: Predictive Biomarkers?	210
Conclusion	214
Further Reading	214
2.7 Immunotherapies in Lymphoma	217
Introduction	217
Monoclonal Antibodies	217
Interferons	219
Vaccination	220
Immune Checkpoint Inhibitors	221
Chimeric Antigen Receptor-T cell Therapy	224
Bispecific Antibodies	227
Further Reading	228

2.8 Gynaecological Malignancies	230
The Role of Immunotherapy in Ovarian Cancer	230
The Role of Immunotherapy in Cervical Cancer	235
The Role of Immunotherapy in Endometrial Cancer	238
Further Reading	241



Section 3: Implications for clinical practice

3.1 Management of Adverse Events Related to Immune Checkpoint Blockade	245
Definition	245
Processes Involved	245
Global Management	246
Clinical Results	247
Further Reading	256
3.2 Immune Checkpoint Blockade: Response Patterns and Assessment of Response	258
The Problem	258
Response Patterns in Immunotherapy	258
Criteria for Response	261
Potential Future Developments	264
Further Reading	266
3.3 Immunotherapy in Special Populations	267
Introduction	267
Clinical Results/Patient Groups	268
Potential Future Developments	275
Further Reading	276
3.4 Cancer Immunotherapy Trials: Challenges and Opportunities	278
Introduction	278
Lessons from Pre-checkpoint Inhibitor Immunotherapy	280
Optimising Contemporary Immunotherapy Clinical Trials	282
Summary	285
Further Reading	286

3.5 Future Perspectives	287
Introduction	287
Precision Immunotherapy	288
Conclusions	294
Further Reading	295
Index	296